- Home
- Media Center
- Press releases
- Corporate
Corporate
SIMPONI® Receives European Commission Approval For Treatment Of Non-Radiographic Axial Spondyloarthritis
Approval Marks Fifth Indication for SIMPONI in Europe
Depuy Synthes Companies Announces Five-Year Cooperation Agreement With The AO Foundation
Agreement Continues 55-Year History of Clinical Innovation and Professional Education
Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
Marks a critical step forward for the investigational human monoclonal antibody (mAb)
Data at EULAR 2015 Showcase Commitment of Janssen to Advancing Innovative Treatments for Immune and Inflammatory Diseases
New data highlights efficacy and safety of STELARA® (ustekinumab), SIMPONI® (golimumab), sirukumab and guselkumab
Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients
Results from the Phase 2 MMY2002 trial (Abstract LBA8512) featured in the official press program of the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)
Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia
Phase 3 data (abstract LBA7005) featured in the official press program of the 51st annual meeting of the American Society of Clinical Oncology
STELARA® Receives CHMP Positive Opinion For Treatment Of Adolescents With Moderate To Severe Psoriasis In Europe
STELARA Recommended for Approval in Paediatric Patients 12 Years and Older with Moderate to Severe Psoriasis
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Non-Radiographic Axial Spondyloarthritis In Europe
SIMPONI Recommended for Approval in Adult Patients with Severe Active Non-Radiographic Axial Spondyloarthritis